Streetbeat News

Earnings

WOLF

Wolfspeed, Inc. (NYSE:WOLF) reported Q3 results with a larger loss and lower sales than expected, leading to a 3.4% drop in shares. Despite missing estimates, CEO Gregg Lowe highlighted operational milestones and progress in their Mohawk Valley and North Carolina facilities. Analysts from Mizuho, Susquehanna, and TD Cowen adjusted their price targets and ratings for Wolfspeed following the earnings announcement.

Portfolio Pulse from Avi Kapoor

May 02, 2024 | 12:45 pm

NOVA

Sunnova Energy International's shares surged following the announcement of Q1 adjusted EPS results that exceeded expectations.

Portfolio Pulse from Benzinga Newsdesk

May 02, 2024 | 12:44 pm

HWM

Howmet Aerospace projects its Q2 2024 adjusted EPS to be between $0.57 and $0.59, surpassing the estimated $0.54. The company also forecasts revenue to be between $1.825B and $1.845B, exceeding the expected $1.774B.

Portfolio Pulse from Benzinga Newsdesk

May 02, 2024 | 12:43 pm

ICE

Intercontinental Exchange shares are trading lower following the report of their Q1 earnings.

Portfolio Pulse from Benzinga Newsdesk

May 02, 2024 | 12:42 pm

DXYN

Dixie Gr (NASDAQ:DXYN) reported a Q1 EPS of $(0.16), down from $(0.11) YoY, with sales of $65.25M, a decrease of 2.73% from $67.08M YoY.

Portfolio Pulse from Benzinga Newsdesk

May 02, 2024 | 12:41 pm

IRMD

IRADIMED projects its 2024 revenues to be in the range of $72M-$74M, aligning closely with the consensus estimate of $72.56M.

Portfolio Pulse from Benzinga Newsdesk

May 02, 2024 | 12:41 pm

IRMD

IRADIMED anticipates its Q2 adjusted EPS to be between $0.36 and $0.39, surpassing the consensus estimate of $0.35.

Portfolio Pulse from Benzinga Newsdesk

May 02, 2024 | 12:41 pm

IRMD

IRADIMED anticipates its Q2 adjusted EPS to be in the range of $1.52-$1.62, surpassing the consensus estimate of $1.38.

Portfolio Pulse from Benzinga Newsdesk

May 02, 2024 | 12:41 pm

IRMD

IRADIMED anticipates Q2 revenues to be between $17.6M and $17.8M, slightly below the consensus estimate of $17.88M.

Portfolio Pulse from Benzinga Newsdesk

May 02, 2024 | 12:40 pm

ALLR

EBS

LUNG

Allarity Therapeutics (ALLR) shares surged 151% following positive Phase 2 trial results for Stenoparib in ovarian cancer. Pulmonx (LUNG) shares rose 29% on strong Q1 financials. Emergent Biosolutions (EBS) shares increased 83% after announcing operational changes and Q1 financial results.

Portfolio Pulse from ryanfaloona@benzinga.com

May 02, 2024 | 12:39 pm